Q1: growth recovery and margin improvements with solid FCF. We tweak our '24e sales and adj. EBITA estimates. Share is trading at 8.6x '24e EV/EBITA adj.
A miss, but keep in mind Q1 is ~5% of FY EBIT. We cut '24e-'26e adj. EBIT by 3-1%, some risk of more price pressure. Share trading at 13-10x '24e-'25e EV/EBIT.
Orders recover from Q4 low, NWC release supports fantastic FCF. Some one-offs weigh on profitability, expect margins to improve. Management seems upbeat on M&A market, acquisitions in '24 likely.
Strong y-o-y growth: EEs +18%, SCs +36%, sales +22%. EBIT margin 23% (25%), ~33% adjusted for FX effects. End-of-life programme in H2 will be partly offset by others ramping.
Q1e: sales +41% y-o-y, ~10% EBIT margin (SDR now consolidated). Raising '24e EPS by 22% on huge unrealised Q1e investment gain. Paper prices still high, but Salling deal lifts '25e-'26e EBIT by 1-3%.
Geographical diversity gives resilience - UK grew 6% org. Thebalux delivered a strong 25% margin; first full quarter in the group. Share trading at 7x '24e EBITA vs historical avg. 7-11x NTM.
Solid 7% organic growth in Q1, underlying was even better. Another $3m in restructuring costs reveals margin pressure. Maintain FV 25-37 after smaller EPS changes.
Q1e: We expect 25% ARR growth and adj. EBITDA of DKK -1.9m. Likely to reiterate FY'24 guidance with no material change in demand. FTE reduction lifts '24e-'26e adj. EBITDA by 19-5%.
Q1 sales hurt by lower US sales, but other regions contributed well. Fine-tuned sales estimates, but we lift our GM assumptions. Ovzon-3 sales to gradually ramp-up in H2e, 10% FCF yield in '25e.